Generic Drug Maker Amneal Pharmaceuticals Is Positioned To Growth Well Ahead Of Peers, Analyst Upgrades Stock

JP Morgan upgrades Amneal Pharmaceuticals, citing strong Crexont sales, robust generics growth, and a higher 2025 revenue forecast, with peak sales over $300 million. Latest Ratings for AMRX Date Firm Action From To Mar 2021 Goldman Sachs Upgrades Sell Buy Dec 2020 Guggenheim Upgrades Neutral Buy Nov 2020 SVB Leerink Maintains Market Perform View More…

Read More